docetaxel + osimertinib

Docetaxel + osimertinib is a combination drug regimen used primarily for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations. Docetaxel is a chemotherapy agent that works by inhibiting microtubule depolymerization, thereby disrupting mitosis and inducing apoptosis in cancer cells. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that irreversibly binds to mutant forms of EGFR, including T790M resistance mutation, blocking downstream signaling pathways involved in tumor growth and survival. This combination has been studied to improve progression-free survival compared to osimertinib monotherapy and is used after prior treatments such as platinum-based chemotherapy or as part of combination regimens with platinum agents. The FDA approved the use of osimertinib with platinum-based chemotherapy for EGFR-mutated NSCLC based on clinical trial data showing improved outcomes[1][2].